{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:28:01Z","timestamp":1780050481812,"version":"3.53.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12328-023-01754-5","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T17:02:56Z","timestamp":1673024576000},"page":"198-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plasmablastic lymphoma occurring in ulcerative colitis during treatment with immunosuppressive therapy"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-505X","authenticated-orcid":false,"given":"Hideharu","family":"Ogiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusaku","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Horiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuho","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Iishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"1754_CR1","first-page":"321","volume-title":"IARC Press","author":"E Campo","year":"2017","unstructured":"Campo E, Stein H, Harris NL. Plasmablastic lymphoma. In: Lyon F, editor. IARC Press. Campo E, Harris NL: WHO classification of Tumors of hematopoietic and Lymphoid Tissues. Serdlow SH; 2017. p. 321\u20132."},{"key":"1754_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","volume":"89","author":"HJ Delecluse","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413\u201320.","journal-title":"Blood"},{"key":"1754_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1100\/tsw.2011.59","volume":"11","author":"JJ Castillo","year":"2011","unstructured":"Castillo JJ, Reagan JL. Plasmablastic lymphoma: a systematic review. ScientificWorldJournal. 2011;11:687\u201396.","journal-title":"ScientificWorldJournal"},{"key":"1754_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","volume":"38","author":"J Morscio","year":"2014","unstructured":"Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014;38:875\u201386.","journal-title":"Am J Surg Pathol"},{"key":"1754_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/BLCTT.S142814","volume":"8","author":"A Lopez","year":"2018","unstructured":"Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018;8:63\u201370.","journal-title":"Blood Lymphat Cancer"},{"key":"1754_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/annonc\/mdh399","volume":"15","author":"J Teruya-Feldstein","year":"2004","unstructured":"Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol. 2004;15:1673\u20139.","journal-title":"Ann Oncol"},{"key":"1754_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/jcp.2006.037556","volume":"60","author":"M Redmond","year":"2007","unstructured":"Redmond M, Quinn J, Murphy P, et al. Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn\u2019s disease after immunosuppressive therapy. J Clin Pathol. 2007;60:80\u20131.","journal-title":"J Clin Pathol"},{"key":"1754_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.crohns.2011.07.002","volume":"5","author":"R Plaza","year":"2011","unstructured":"Plaza R, Ponferrada A, Benito DM, et al. Plasmablastic lymphoma associated to Crohn\u2019s disease and hepatitis C virus chronic infection. J Crohns Colitis. 2011;5:628\u201332.","journal-title":"J Crohns Colitis"},{"key":"1754_CR9","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1016\/j.crohns.2012.07.025","volume":"7","author":"L Liu","year":"2013","unstructured":"Liu L, Charabaty A, Ozdemirli M. EBV-associated plasmablastic lymphoma in a patient with Crohn\u2019s disease after adalimumab treatment. J Crohns Colitis. 2013;7:e118\u20139.","journal-title":"J Crohns Colitis"},{"key":"1754_CR10","doi-asserted-by":"publisher","first-page":"11894","DOI":"10.3748\/wjg.v20.i33.11894","volume":"20","author":"L Luria","year":"2014","unstructured":"Luria L, Nguyen J, Zhou J, et al. Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review. World J Gastroenterol. 2014;20:11894\u2013903.","journal-title":"World J Gastroenterol"},{"key":"1754_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/PAT.0000000000000039","volume":"46","author":"C Liu","year":"2014","unstructured":"Liu C, Varikatt W, P\u2019ng CH. Plasmablastic lymphoma presenting as a colonic stricture in Crohn\u2019s disease. Pathology. 2014;46:77\u20139.","journal-title":"Pathology"},{"key":"1754_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.prp.2015.09.012","volume":"211","author":"M Zanelli","year":"2015","unstructured":"Zanelli M, Ragazzi M, Valli R, et al. Unique presentation of a plasmablastic lymphoma superficially involving the entire large bowel. Pathol Res Pract. 2015;211:1030\u20133.","journal-title":"Pathol Res Pract"},{"key":"1754_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00277-015-2497-6","volume":"95","author":"SW Maung","year":"2016","unstructured":"Maung SW, Desmond R, McHugh J, et al. A coincidence or a rare occurrence? A case of plasmablastic lymphoma of the small intestines following infliximab treatment for Crohn\u2019s disease. Ann Hematol. 2016;95:149\u201350.","journal-title":"Ann Hematol"},{"key":"1754_CR14","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.cgh.2017.07.036","volume":"16","author":"G Ghosh","year":"2018","unstructured":"Ghosh G, Jacob V, Wan D. Plasmablastic lymphoma in a patient With Crohn\u2019s disease After extensive immunosuppressive therapy. Clin Gastroenterol Hepatol. 2018;16:e41\u20132.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1754_CR15","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1111\/1346-8138.15600","volume":"47","author":"S Sato","year":"2020","unstructured":"Sato S, Nakahara M, Kato K, et al. Plasmablastic lymphoma occurring in the vicinity of enterocutaneous fistula in Crohn\u2019s disease. J Dermatol. 2020;47:e442\u20133.","journal-title":"J Dermatol"},{"key":"1754_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","volume":"17","author":"L Beaugerie","year":"2019","unstructured":"Beaugerie L, Kirchgesner J. Balancing benefit vs risk of immunosuppressive therapy for individual patients With inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:370\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1754_CR17","doi-asserted-by":"publisher","first-page":"e844","DOI":"10.1016\/j.cgh.2014.05.015","volume":"13","author":"DS Kotlyar","year":"2015","unstructured":"Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:e844.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1754_CR18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","volume":"18","author":"L Beaugerie","year":"2020","unstructured":"Beaugerie L, Rahier JF, Kirchgesner J. Predicting, preventing, and managing treatment-related complications in patients With inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18:1324-1335.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1754_CR19","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679\u201386.","journal-title":"JAMA"},{"key":"1754_CR20","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450\u201361.","journal-title":"Gastroenterology"},{"key":"1754_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489\u2013526.","journal-title":"J Gastroenterol"},{"key":"1754_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","volume":"10","author":"T Jess","year":"2012","unstructured":"Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639\u201345.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1754_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","volume":"126","author":"M Rutter","year":"2004","unstructured":"Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451\u20139.","journal-title":"Gastroenterology"},{"key":"1754_CR24","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","volume":"111","author":"K Ekstr\u00f6m Smedby","year":"2008","unstructured":"Ekstr\u00f6m Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029\u201338.","journal-title":"Blood"},{"key":"1754_CR25","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/ecco-jcc\/jjaa186","volume":"15","author":"M Muller","year":"2021","unstructured":"Muller M, D\u2019Amico F, Bonovas S, et al. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. J Crohns Colitis. 2021;15:840\u201359.","journal-title":"J Crohns Colitis"},{"key":"1754_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/CEG.S237646","volume":"13","author":"J Dahmus","year":"2020","unstructured":"Dahmus J, Rosario M, Clarke K. Risk of lymphoma associated with anti-TNF therapy in patients with inflammatory bowel disease: implications for therapy. Clin Exp Gastroenterol. 2020;13:339\u201350.","journal-title":"Clin Exp Gastroenterol"},{"key":"1754_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/annonc\/mdw684","volume":"28","author":"E Tchernonog","year":"2017","unstructured":"Tchernonog E, Faurie P, Coppo P, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28:843\u20138.","journal-title":"Ann Oncol"},{"key":"1754_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/gast.2002.30328","volume":"122","author":"GA Dayharsh","year":"2002","unstructured":"Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72\u20137.","journal-title":"Gastroenterology"},{"key":"1754_CR29","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","volume":"51","author":"JJ Castillo","year":"2010","unstructured":"Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51:2047\u201353.","journal-title":"Leuk Lymphoma"},{"key":"1754_CR30","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/modpathol.2013.73","volume":"26","author":"A Valera","year":"2013","unstructured":"Valera A, Colomo L, Mart\u00ednez A, et al. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Mod Pathol. 2013;26:1329\u201337.","journal-title":"Mod Pathol"},{"key":"1754_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-015-0163-z","volume":"8","author":"S Loghavi","year":"2015","unstructured":"Loghavi S, Alayed K, Aladily TN, et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015;8:65.","journal-title":"J Hematol Oncol"},{"key":"1754_CR32","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1002\/cncr.27551","volume":"118","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Furman M, Beltr\u00e1n BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118:5270\u20137.","journal-title":"Cancer"},{"key":"1754_CR33","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1080\/10428194.2017.1416365","volume":"59","author":"C Dittus","year":"2018","unstructured":"Dittus C, Grover N, Ellsworth S, et al. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leuk Lymphoma. 2018;59:2121\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1754_CR34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.15156","volume":"184","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Guerrero-Garcia T, Baldini F, et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019;184:679\u201382.","journal-title":"Br J Haematol"},{"key":"1754_CR35","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","volume":"20","author":"MM Al-Malki","year":"2014","unstructured":"Al-Malki MM, Castillo JJ, Sloan JM, et al. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014;20:1877\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1754_CR36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","volume":"9","author":"V Annese","year":"2015","unstructured":"Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9:945\u201365.","journal-title":"J Crohns Colitis"},{"key":"1754_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11894-021-00829-y","volume":"23","author":"L Sattler","year":"2021","unstructured":"Sattler L, Hanauer SB, Malter L. Immunomodulatory agents for treatment of patients with inflammatory bowel disease (review safety of anti-TNF, anti-integrin, anti IL-12\/23, JAK inhibition, sphingosine 1-phosphate receptor modulator, azathioprine\/6-MP and methotrexate). Curr Gastroenterol Rep. 2021;23:30.","journal-title":"Curr Gastroenterol Rep"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01754-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-023-01754-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01754-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:28:00Z","timestamp":1744158480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-023-01754-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1007\/s12328-023-01754-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient for inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}